Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
Originator Sued Hikma For Induced Infringement Late Last Year
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
You may also be interested in...
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.
Teva was in position to introduce further generic competition to Amarin’s Vascepa following legal setbacks for the originator. However, the firm’s ANDA has since been listed as discontinued.
Certiorari review of a Federal Circuit decision invalidating Vascepa patents “is not warranted,” Hikma and Dr Reddy’s Laboratories have argued, claiming that the premise of originator Amarin’s petition to the US Supreme Court is “false.”